65,437 trials
Pain, Postoperative
Primary: Visual Analogue Scale (VAS) Pain Score — 2.5; 4.4 points on a scale — p=.003
Pleural Neoplasms
Primary: Pathological Complete Response — 3 participants
Erectile Dysfunction
Primary: International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) — 10.96…
Congestive Heart Failure
Primary: Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography — -18.36; -20.81 mL/m^2
Infections, Rotavirus
Primary: Presence of Rotavirus Vaccine Strain in Any Stool Sample From Twin Receiving Placebo. — 15 subjects
Fibromyalgia
Primary: Change From Baseline to Week 4 in Pain Visual Analog Scale (VAS) Score — -18.1 mm
Diabetic Neuropathies · Neuralgia
Primary: Daily Pain Rating Scale (DPRS)- Mean Pain Score (ITT Population) — 4.63; 5.13 score on scale — p=0.049
Infections, Rotavirus
Primary: Number of Subjects Reporting Grade "2" or Grade "3" Fever, Vomiting or Diarrhea — 26; 28 Participants
Melanoma
Primary: Overall Survival — 9.13; 9.36 Months — p=0.9999
Chronic Kidney Disease · Vitamin D Deficiency
Primary: 25-hydroxyvitamin D — 18.6; 17.3; 19.5; 49.4 ng/mL
Glioblastoma
Primary: Adverse Events With an Incidence of Greater Than or Equal to 20% — 25; 17; 17; 15 Participants
Pharyngitis
Primary: Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose — 21.0; 9.4 units on a scale * hours — p=0.0003
Acne Vulgaris
Primary: Success Rate on the Investigator's Global Assessment — 37.9; 21.8; 26.7; 17.9 Percentage of participants
Hepatitis C, Chronic
Primary: Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment — 70 Participants
Skin Graft
Primary: Complete Wound Healing — 13.9; 7.2; 5.7 Days — p=0.05